CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

P. Sharma, B. Escudier, D. F. McDermott, S. George, H. J. Hammers, S. Srinivas, S. S. Tykodi, J. A. Sosman, G. Procopio, E. R. Plimack, D. Castellano, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. C. Gauler, T. Ueda, L. A. Xu, I. M. Waxman, R. J. Motzer

Research output: Contribution to journalMeeting abstractResearch

LanguageEnglish
PagesS708
Number of pages1
JournalEuropean Journal of Cancer
Volume51
Issue numberSupplement 3
DOIs
Publication statusPublished - Sep 2015
Externally publishedYes
EventEuropean Cancer Congress - Vienna, Austria
Duration: 25 Sep 201529 Sep 2015

Cite this

Sharma, P., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., ... Motzer, R. J. (2015). CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). European Journal of Cancer, 51(Supplement 3), S708. https://doi.org/10.1016/S0959-8049(16)31926-8
Sharma, P. ; Escudier, B. ; McDermott, D. F. ; George, S. ; Hammers, H. J. ; Srinivas, S. ; Tykodi, S. S. ; Sosman, J. A. ; Procopio, G. ; Plimack, E. R. ; Castellano, D. ; Gurney, H. ; Donskov, F. ; Bono, P. ; Wagstaff, J. ; Gauler, T. C. ; Ueda, T. ; Xu, L. A. ; Waxman, I. M. ; Motzer, R. J. / CheckMate 025 : a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). In: European Journal of Cancer. 2015 ; Vol. 51, No. Supplement 3. pp. S708.
@article{9530c117015a4f6bb5bf8607f485dda1,
title = "CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)",
author = "P. Sharma and B. Escudier and McDermott, {D. F.} and S. George and Hammers, {H. J.} and S. Srinivas and Tykodi, {S. S.} and Sosman, {J. A.} and G. Procopio and Plimack, {E. R.} and D. Castellano and H. Gurney and F. Donskov and P. Bono and J. Wagstaff and Gauler, {T. C.} and T. Ueda and Xu, {L. A.} and Waxman, {I. M.} and Motzer, {R. J.}",
year = "2015",
month = "9",
doi = "10.1016/S0959-8049(16)31926-8",
language = "English",
volume = "51",
pages = "S708",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Pergamon Press",
number = "Supplement 3",

}

Sharma, P, Escudier, B, McDermott, DF, George, S, Hammers, HJ, Srinivas, S, Tykodi, SS, Sosman, JA, Procopio, G, Plimack, ER, Castellano, D, Gurney, H, Donskov, F, Bono, P, Wagstaff, J, Gauler, TC, Ueda, T, Xu, LA, Waxman, IM & Motzer, RJ 2015, 'CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)', European Journal of Cancer, vol. 51, no. Supplement 3, pp. S708. https://doi.org/10.1016/S0959-8049(16)31926-8

CheckMate 025 : a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). / Sharma, P.; Escudier, B.; McDermott, D. F.; George, S.; Hammers, H. J.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Procopio, G.; Plimack, E. R.; Castellano, D.; Gurney, H.; Donskov, F.; Bono, P.; Wagstaff, J.; Gauler, T. C.; Ueda, T.; Xu, L. A.; Waxman, I. M.; Motzer, R. J.

In: European Journal of Cancer, Vol. 51, No. Supplement 3, 09.2015, p. S708.

Research output: Contribution to journalMeeting abstractResearch

TY - JOUR

T1 - CheckMate 025

T2 - European Journal of Cancer

AU - Sharma, P.

AU - Escudier, B.

AU - McDermott, D. F.

AU - George, S.

AU - Hammers, H. J.

AU - Srinivas, S.

AU - Tykodi, S. S.

AU - Sosman, J. A.

AU - Procopio, G.

AU - Plimack, E. R.

AU - Castellano, D.

AU - Gurney, H.

AU - Donskov, F.

AU - Bono, P.

AU - Wagstaff, J.

AU - Gauler, T. C.

AU - Ueda, T.

AU - Xu, L. A.

AU - Waxman, I. M.

AU - Motzer, R. J.

PY - 2015/9

Y1 - 2015/9

U2 - 10.1016/S0959-8049(16)31926-8

DO - 10.1016/S0959-8049(16)31926-8

M3 - Meeting abstract

VL - 51

SP - S708

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - Supplement 3

ER -